Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York2Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, New York, New York3Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York.
Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York.
JAMA Oncol. 2016 Oct 1;2(10):1326-1332. doi: 10.1001/jamaoncol.2016.1291.
While adjuvant hormonal therapy (HT) reduces mortality for women with nonmetastatic breast cancer, nonadherence to HT is common.
We investigated the association between patterns of prior nonadherence to medications for chronic conditions with HT nonadherence.
DESIGN, SETTING, AND PARTICIPANTS: For this retrospective cohort study, the MarketScan database was scanned for women 18 years and older who had been diagnosed with nonmetastatic breast cancer between January 1, 2010, and December 31, 2012, and who filled 2 or more prescriptions for tamoxifen and/or an aromatase inhibitor.
Nonadherence to medications for 6 chronic conditions (hypertension, hyperlipidemia, gastroesophageal reflux disease, thyroid disease, diabetes, osteoporosis) in the 12 months before diagnosis was defined as a medication possession ratio (MPR) less than 80%. Nonadherence to HT was defined as an MPR less than 80% between the first and last prescription for HT up to 2 years.
Multivariable logistic regression was used to determine the association between prior medication nonadherence and HT nonadherence.
Of 21 255 women treated with adjuvant HT, 3314 (15.6%) were nonadherent, and age (<55 or ≥75 years vs 55-64 years), higher 30-day out-of-pocket costs, and increased comorbidities were associated with nonadherence. Women without prior medications for 1 of the chronic conditions (n = 7828 [37%]) had an 18.4% nonadherence rate to HT. Those who used 1 or more medication prior to HT and were adherent (n = 9223 [43%]) had a 9.8% nonadherence rate to HT (relative to those without prior medications: odds ratio [OR] 0.56; 95% CI, 0.50-0.61), while those who were nonadherent to their chronic medications (n = 4214 [20%]) had a 23.1% nonadherence rate to HT (OR 1.43; 95% CI, 1.30-1.58). Adherence and nonadherence for medications for each of the 6 medical conditions was associated with adherence or nonadherence for HT, respectively.
We found that nonadherence to medications for chronic conditions prior to HT was associated with greater nonadherence to oral HT in patients with breast cancer. Medication nonadherence history may play an important role in determining patients at risk for nonadherence to a subsequent medication for a different illness, such as HT, and a potential target for future interventions.
虽然辅助激素治疗(HT)降低了非转移性乳腺癌患者的死亡率,但 HT 不依从的情况很常见。
我们研究了先前对慢性疾病药物的不依从与 HT 不依从之间的关系。
设计、地点和参与者:这项回顾性队列研究对市场扫描数据库进行了扫描,以确定在 2010 年 1 月 1 日至 2012 年 12 月 31 日期间被诊断为非转移性乳腺癌的 18 岁及以上的女性,她们至少开了两种他莫昔芬和/或芳香酶抑制剂的处方。
在诊断前的 12 个月内,6 种慢性疾病(高血压、高血脂、胃食管反流病、甲状腺疾病、糖尿病、骨质疏松症)的药物使用率(MPR)低于 80%被定义为药物使用率不足。HT 不依从性定义为 HT 治疗的前两个处方之间 MPR 小于 80%,直至 2 年。
多变量逻辑回归用于确定先前药物不依从性与 HT 不依从性之间的关系。
在接受辅助 HT 治疗的 21255 名女性中,有 3314 名(15.6%)不依从,年龄(<55 岁或≥75 岁比 55-64 岁)、30 天内较高的自付费用和增加的合并症与不依从有关。没有任何一种慢性疾病的药物治疗史(n=7828[37%])的女性 HT 不依从率为 18.4%。那些在 HT 前使用过一种或多种药物且依从性(n=9223[43%])的女性 HT 不依从率为 9.8%(与无药物治疗史的女性相比:比值比[OR]0.56;95%CI,0.50-0.61),而那些对慢性药物不依从的女性(n=4214[20%]) HT 不依从率为 23.1%(OR 1.43;95%CI,1.30-1.58)。6 种医疗条件的每种药物的依从性和不依从性与 HT 的依从性或不依从性分别相关。
我们发现,HT 前慢性疾病药物的不依从与乳腺癌患者对口服 HT 的不依从性更大有关。药物不依从史可能在确定随后对不同疾病(如 HT)药物的依从性风险方面发挥重要作用,这可能是未来干预的潜在目标。